Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

6 results
Display

Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis

Imakiire S, Takedatsu H, Mitsuyama K, Sakisaka H, Tsuruta K, Morita M, Kuno N, Abe K, Funakoshi S, Ishibashi H, Yoshioka S, Torimura T, Hirai F

Background/Aims: Proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) is a serologic marker for granulomatosis with polyangiitis. However, recent studies have also shown their role as diagnostic markers for ulcerative colitis (UC)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Hisamatsu , Kunisaki R, Nakamura S, Tsujikawa , Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M, CERISIER Trial group

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk factors for severity of colonic diverticular hemorrhage

Kinjo K, Matsui T, Hisabe T, Ishihara H, Kojima T, Chuman K, Yasukawa S, Beppu T, Koga A, Ishikawa S, Kishi M, Takatsu N, Hirai F, Yao K, Ueki T, Washio M

BACKGROUND/AIMS: Colonic diverticular hemorrhage (DH) was a rare disease until the 1990s, and its incidence has increased rapidly since 2000 in Japan. In recent years, colonic DH has been the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

Koga A, Matsui T, Takatsu N, Takada Y, Kishi M, Yano Y, Beppu T, Ono Y, Ninomiya K, Hirai F, Nagahama T, Hisabe T, Takaki Y, Yao K, Imaeda H, Andoh A

BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Inoue N, Kobayashi , Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson A, Thakkar RB, Hibi T

BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current status of endoscopic balloon dilation for Crohn's disease

Hirai F

The therapeutic target in Crohn's disease (CD) has been raised to the achievement of mucosal healing. Although effective treatments that target cytokines and other molecules has been widely used for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr